-+ 0.00%
-+ 0.00%
-+ 0.00%

Mineralys' Lorundrostat Lowers Blood Pressure in Kidney Disease Patients in Phase 3 Trial

PUBT·10/22/2026 22:40:24
Listen to the news
Mineralys' Lorundrostat Lowers Blood Pressure in Kidney Disease Patients in Phase 3 Trial
  • Mineralys Therapeutics presented new lorundrostat results from its pivotal Phase 3 Launch-HTN trial at ASN Kidney Week on Oct. 22, 2026.
  • Lorundrostat significantly lowered blood pressure versus placebo, with similar benefits in participants with or without chronic kidney disease.
  • Treatment also reduced a marker of kidney damage in participants with chronic kidney disease, with an acceptable safety profile.
  • The FDA is reviewing lorundrostat for hypertension alongside other antihypertensive drugs, with a target decision date of Dec. 22, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221840PRIMZONEFULLFEED9851723) on October 22, 2026, and is solely responsible for the information contained therein.